Micron Technology, Inc. vs Viatris Inc — how do they compare? Micron Technology, Inc. trades at $929.4 (market cap $980.90B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Micron Technology, Inc. is far larger — about 52.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| MU | VTRS | |
|---|---|---|
Market Cap | $980.90B | $18.69B |
Sector | Technology | Health |
52-Week High | $1.21K | $17.86 |
52-Week Low | $115.79 | $9.49 |
Enterprise Value | $961.25B | $30.80B |
Dividend Yield | 0.06% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $925.24, up 7.46% with strong earnings momentum after beating Q1 2026 EPS estimates of $20.98 with $25.11. The stock shows bearish technical signals despite robust fundamentals including 55.91% net margin and 32.62% ROE. Recent news highlights AI-driven memory demand growth but concerns about cyclicality and competitive threats from new entrants like SpaceX's Terrafab facility.
Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target, though technical weakness and memory market cyclicality pose near-term risks. The company's strategic customer agreements provide revenue visibility through 2030, supporting long-term growth potential despite current bearish technical indicators.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Trailing returns across standard periods
Latest headlines on both assets
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →